Cite

HARVARD Citation

    Narula, N. et al. (n.d.). P607 Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease. Journal of Crohn's and colitis. p. S420. [Online]. 
  
Back to record